Side-by-side · Research reference

5-Amino-1MQvsGHRP-6

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongDraft8/38 cited

BPhase 1Reviewed10/36 cited

5-Amino-1MQ

NNMT inhibitor · Methylation / SAM modulation

100–200 mgDaily dose (oral)Neelakantan 2018

AnimalEvidence levelNeelakantan 2018

HoursHalf-life (est)

Oral · Once daily fasted

GHRP-6

Hexapeptide GHRP · Strong appetite stimulant

100–200 mcgPer doseBowers 1990

Phase 1Evidence levelBowers 1990

~15 minHalf-lifeMalagón 1999

SQ · Multiple sites · 1–3×/day

01Mechanism of Action

Parameter

5-Amino-1MQ

GHRP-6

Primary target

Nicotinamide N-methyltransferase (NNMT)Neelakantan 2018

Ghrelin receptor (GHS-R1a)Bowers 1990

Pathway

NNMT inhibition → preserved cellular SAM + NAD⁺ → restored methylation balance + ↑ thermogenic gene expressionNeelakantan 2018

GHS-R1a → Gαq → Ca²⁺ → GH release; central appetite driveBowers 2002

Downstream effect

Reversal of HFD-induced obesity in murine models; improved metabolic profileNeelakantan 2018

GH pulse + strong appetite stimulation; modest IGF-1 elevationBowers 2002

Feedback intact?

—

Origin

Selective small-molecule inhibitor designed in academic medicinal chemistry programsNeelakantan 2018

Synthetic hexapeptide; first-generation GHRP from Bowers groupBowers 1990

Antibody development

—

02Dosage Protocols

Parameter

5-Amino-1MQ

GHRP-6

Standard dose

100–200 mg / day oralNeelakantan 2018

Anecdotal community range; murine doses scaled.

100–200 mcg per injectionBowers 1990

Frequency

Once daily, fasted

1–3× per day

Lower / starter dose

50 mg / day

50 mcg per dose

Evidence basis

Animal-strong; no human RCT dataNeelakantan 2018

Phase 1 + clinical practiceBowers 1990

Duration

8–12 weeks per cycle

8–12 weeks on / 4 off

Form

Oral capsule

—

Timing

Morning fasted preferred

Pre-meal preferred for appetite support

Half-life

Hours (estimated; no human PK published)

~15 minMalagón 1999

Reconstitution

—

Bacteriostatic water

04Side Effects & Safety

Parameter

5-Amino-1MQ

GHRP-6

GI symptoms

Mild nausea (anecdotal)

—

Methylation disruption

Theoretical risk if NNMT is over-inhibited (B vitamin metabolism)

—

Long-term safety

Unknown — no human trials

—

Cancer risk

Unclear — NNMT also studied in oncology contexts

Contraindicated in active malignancy

Pregnancy / OB

Avoid

Drug interactions

Theoretical with niacin / B-vitamin supplements

—

Hunger

—

Pronounced — defining feature vs ipamorelin

Cortisol elevation

—

Mild

Prolactin elevation

—

Mild

Injection site reaction

—

Mild

Absolute Contraindications

5-Amino-1MQ

·Pregnancy / breastfeeding
·Active malignancy

GHRP-6

·Active malignancy
·Pregnancy / breastfeeding

Relative Contraindications

5-Amino-1MQ

·Methylation-sensitive conditions (MTHFR mutation)
·Concurrent niacin / NAD+ precursor supplementation (theoretical interference)

GHRP-6

·Severe insulin resistance (appetite-driven caloric load)

05Administration Protocol

Parameter

5-Amino-1MQ

GHRP-6

1. Form

Oral capsule. No injection.

Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL.

2. Administration

Take with water, fasted preferred.

SQ — abdomen. Rotate sites.

3. Timing

Morning fasted.

Pre-meal for appetite support; pre-sleep for GH alignment.

4. Storage

Room temp ≤25 °C, dry place.

Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.

5. Caveat

Monitor B-vitamin status with chronic use.

29–31G, 4–8 mm insulin syringe.